Pfizer has agreed to pay up to $250mn to settle more than 10,000 US lawsuits over cancer risks associated with its now-discontinued heartburn drug Zantac, according to people familiar with the deal.
Pfizer (NYSE ... up to $250M to settle more than 10,000 U.S. lawsuits alleging that the company concealed cancer risks associated with its now-discontinued heartburn drug Zantac.
opens new tab will pay up to $250 million to settle more than 10,000 U.S. lawsuits ... added. Pfizer did not immediately reply to Reuters' request for comment. First approved in 1983, Zantac ...
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. PFE has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a Delaware ...
(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...
Pfizer has agreed to pay between $200m to $250m to settle more than 10,000 US lawsuits over cancer risks associated with Zantac, Financial Times reports, citing two unidentified people briefed on the ...
London: Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday.
(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...
(Reuters) – Pfizer has agreed offer payment of up to $250 million to settle more than 10,000 lawsuits in the United States over cancer risks associated with its now-discontinued heartburn drug Zantac, ...